Kornimate/medical-research-clean huggingface dataset:
understanding and diagnosing allergic disease in twins

Conditions: Allergies

Summary: the purpose of this study is to gain better understanding of how the immune system works in twins with and without allergic disease. healthy volunteers are not specifically targeted. healthy non-allergic study participants may be found through the course of evaluation for the presence of allergies.

the purpose of this study is to study the genetic control and gain better understanding of how the immune system works in twins with and without allergic disease. although healthy volunteers are not specifically targeted, they might be identified when non-allergic study participants are found through the course of evaluation for the presence of allergies.

Eligibility criteria:
inclusion criteria: * twin participants ages 0 to 80 years who are with or without allergy disease. exclusion criteria: * patients with special risks attendant to venipuncture will be excluded.
effects of short-intensity modified constraint-induced movement therapy on hand function in stroke patients.

Conditions: Hemorrhagic Stroke; Ischemic Stroke; Rehabilitation

Summary: to determine effects of short-intensity modified constraint-induced movement therapy on hand function in stroke patients.

the aim of the study is to determine the effects of a short-intensity modified cimt (mcimt) program on hand function in stroke patients. this study will be a randomized controlled trial comprising two groups, an experimental group in which patients will be given short-intensity mcimt along with conventional therapy. a control group, in which participants will be given conventional therapy alone. patients will be assessed with the wolf motor function test, the motor activity log, and the ashworth scale before and after treatment. the data will be analyzed by using spss for windows software version 25. statistical significance will be set at p=0.05.

Eligibility criteria:
inclusion criteria: * patients having the first stroke either ischemic or hemorrhagic (3-24 months after stroke) * patients having mini-mental status examination score (mmse) ≤23/30 * patients having passive range of motion (prom) includes at least 90 degrees shoulder flexion and abduction, 45degrees shoulder external rotation,- 30 degrees elbow extension, and 45 degrees forearm supination and pronation (from a neutral position). at least 10 degrees active wrist extension, 10 degrees abduction/thumb extension, and 10-degree extension at the level of the metacarpophalangeal and interphalangeal joints between the two toes among the ii-iii-iv-v fingers (these movements will be repeated starting from a resting position 3 times in 1 minute). exclusion criteria: * patients having subarachnoid hemorrhage. * patients having motor activity log - the amount of use score ≥2.5 * patients having treatment of upper limb spasticity (e.g., botulinum toxin) in the 3 months prior to the start of the study and/or during its execution.

Keywords: hemorrhagic stroke ischemic stroke rehabilitation
beovu experience uz leuven

Conditions: Age-Related Macular Degeneration

Summary: reporting early real-world clinical data of consecutive patients on the use of beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.

brolucizumab (beovu, novartis, basel, switzerland) is the newest anti-vascular endothelial growth factor (anti-vegf) drug. it received fda approval for the treatment of neovascular age-related macular degeneration (namd) in october 2019 followed by ema approval in february 2020. brolucizumab received marketing approval based on the two pivotal phase 3 clinical trials - hawk and harrier - with a q8/q12 week dosing regimen. potential benefits of brolucizumab are assumed to be related to its low molecular weight with subsequent better tissue penetration as well as higher molar concentration. this could improve the treatment durability and lower the burden for patients and caregivers when dealing with repetitive intravitreal treatments and monitoring visits over a long period of time in a chronic disease. however, safety signals have been reported in both rcts and post-marketing reports, which included the occurrence of intraocular inflammation (ioi) and retinal vasculitis with or without occlusion. in this study we want to share our early results and experience with bolucizumab in uz leuven. by retrospective analysis of a cohort of 17 patients treated with brolucizumab, we evaluate the efficacy of the drug as well as the occurrence of adverse-events, especially intra-ocular inflammation and vasculitis.

Eligibility criteria:
inclusion criteria: 1. diagnosis of neovascular age-related macular degeneration 2. partial response on current anti-vegf treatment or unability to prolong the treatment interval beyond 6 or 8 weeks exclusion criteria: * 1. any form of previous intraocular inflammation 2. any form of previous inflammatory reaction after anti-vegf treatment 3. functionally monophthalmic patients 4. any sign of active intraocular inflammation
effect on beta cell function and glycaemic control after insulin and exenatide sequential therapy

Conditions: Type 2 Diabetes

Summary: whether glp-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.

the uk prospective diabetes study has shown that β-cell function progressively deteriorates over time in people with type 2 diabetes mellitus,irrespective of lifestyle and existing pharmacological interventions. the progressive nature of type 2 diabetes is one of the major challenges in the treatment of affected patients, and agents that could alter the natural history of this condition would add greatly to current treatment approaches.short-term intensive insulin therapy of newly diagnosed type 2 diabetes has been proved improving beta-cell function and usually leading to a temporary remission time,but the remission rate in a year is only about 50%. the effect of glp-1 receptor agonists on beta-cells is stimulation of glucose-dependent insulin release, followed by enhancement of insulin biosynthesis. it is stimulating beta-cell proliferation, induction of islet neogenesis, and inhibition of ß-cell apoptosis. exenatide is an glp-1 receptor agonist. exenatide exerts direct effects on β-cell, which indicates that may contribute to delay disease progression. however, no study has evaluated effect of short-term intensive insulin sequential exenatide therapy model on β-cell function and glycemic remission rate in newly diagnosed type 2 diabetic patients. our hypotheses is whether glp-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.

Eligibility criteria:
inclusion criteria: * newly diagnosed type 2 diabetes without drug treatment * 25-70 years old age * fasting glucose between 7.0-16.7mmol / l * bmi at 20 \~ 35 kg/m2 and stable for at least 3 month(weight fluctuations within three months does not exceed 10%) * females who have no plan of pregnancy during the study exclusion criteria: * acute or chronic complications of diabetes * myocardial infarction or cerebrovascular events within three months * serious gastrointestinal diseases * other serious concomitant diseases * liver or kidney dysfunction:transaminase (alt and ast) greater than 3 times the upper limit of the normal range or creatinine levels greater than 133μmol / l * gad antibodies positive * history of pancreatitis or pancreatic cancer; * pregnant or breastfeeding women. * severe hypertension (blood pressure\> 180/110mmhg) * using corticosteroids, immunosuppressants and cytotoxic therapy.

Keywords: the newly onset type 2 diabetes short-term insulin treatment exenatide sequential therapy beta cell function glycaemic remission
iranian traditional mouth rinse punica granatum pleniflora (golnaar) in treatment of gingivitis in diabetic patients

Conditions: Gingivitis

Summary: this is a triple-blinded randomized clinical trial to evaluate the effect of an iranian traditional mouth rinse (punica granatum pleniflora or "golnaar" mouthrinse) on treatment of diabetic gingivitis and compare it with chlorhexidine (0.2%).

among diabetic patients who refer to motahhari clinic of shiraz university of medical sciences 80 volunteers who have gingivitis and aged between 20 to 65 years old and fulfill other inclusion criteria, are randomly assigned to intervention or control groups. all of the patients will undergo a training panel about mouth hygiene and receive a pack of a toothbrush, a toothpaste, a dental floss and a mouth rinse. they are asked to return after 2 weeks for the second evaluation and taking tooth bleaching. the demographic and general information of all participants are taken and the primary outputs (plaque index and bleeding on probe) are measured at the beginning, after 2 weeks and after 4 weeks. all the examinations are done by one trained person and patients, practitioner and statistical analyser are blind to the interventions.

Eligibility criteria:
inclusion criteria: * to have gingivitis * controlled diabetes mellitus \[fbs\<130mg/dl \& glycosilated hemoglobin (a1c)\<7%\] * presence of gingivitis * having at least 20 teeth * no history of hypersensitivity reaction * age between 20 to 65 years * agreement to participate in the study exclusion criteria: * history of hypersensitivity reaction * smoking * systemic diseases (kidney, liver or rheumatologic diseases) * to have a pocket depth of more than 5 * consumption of antibiotics, corticosteroids or nonsteroidal anti-inflammatory drugs in the past 3 months and during the study period

Keywords: gingivitis diabetes mellitus medicine, traditional herbal medicine punica granatum
a study to evaluate the antibody response of influenza vaccination following concomitant exposure to bimekizumab in healthy subjects

Conditions: Healthy Volunteers

Summary: the purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.


Eligibility criteria:
inclusion criteria: * subject is male or female aged ≥18 years and ≤55 years at the screening visit * subject must have a blood test with at least two influenza antibody titers ≤1/10 at the screening visit and have not developed any flu-like illness 2 weeks before the start of the study * female subjects of childbearing potential must not be lactating and have a negative serum pregnancy test at the screening visit, which is confirmed to be negative by urine testing prior to administration of bimekizumab. female subjects of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 20 weeks after their last dose of the investigational medicinal product (imp) * subject has a body weight of ≥45 kg and body mass index (bmi) between 18 and 32 kg/m2 (inclusive), at the screening visit exclusion criteria: * subject has a known hypersensitivity to any excipients of bimekizumab * subject has a history of hypersensitivity to the influenza vaccine * subject is legally institutionalized or has a mental health condition or related care provision (eg, guardianship) that would impede the subject from providing voluntary informed consent to participate in the study * female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with childbearing potential who is not using a medically accepted birth control method * male subjects who are planning a partner pregnancy during the study * subjects receiving vaccination of any kind within the 52 weeks prior to the screening visit or the influenza vaccination within 2 years prior to the screening visit. live vaccines are not allowed during the study or for 20 weeks after the last dose of investigational medicinal product (imp) * subject has a current or past history of gastrointestinal ulceration or other gastrointestinal disease, such as inflammatory bowel disease * subject has an active infection * subject has concurrent acute or chronic viral hepatitis b or c or human immunodeficiency virus (hiv) infection or human t-cell lymphotropic virus type-1 (htlv-1)

Keywords: bkz ucb4940 healthy subjects
dysthyroidism and female sexual function

Conditions: Sexuality; Thyroid

Summary: the aim of the study is to evaluate the incidence of sexual dysfunction in presence of dysthyroidism and the impact of restoring euthyroidism on female sexual function

hormonal component plays a crucial role in sexual function. hypothyroidism and hyperthyroidism may be associated with any form of sexual dysfunction in men but only a few studies reported the relationship between thyroid dysfunction and female sexuality. the study is an observational study. an informed consent will be obtained from all patients before the study. the aim of the study is: * to evaluate the incidence of sexual dysfunction in presence of dysthyroidism and the impact of restoring euthyroidism on female sexual function (evaluated with the female sexual function index) * to evaluate the influence of hormonal changes on the emotional and psychological wellness (evalueted with the middle sex hospital questionnaire) * to evaluate the influence of hormonal changes on the satisfaction of body image (evalueted with the body uneasiness test) * to evaluate the influence of hormonal changes on the distress related to sexuality (evaluated with the female sexual distress scale). the investigators espect to enroll a total of 50 sexually active hyperthyroidic/hypothyroidic women in this study in about 7 months. statistical analyses will be performed using the statistical package for the social sciences

Eligibility criteria:
inclusion criteria: * informed consent * hyperthyroidic or hypothyroiditic women * sexually active women exclusion criteria: * age \< 18 y * no sexual activity * pregnancy * psychiatric disease
effect of dumbbell exercise on arteriovenous fistula in patients with hemodialysis

Conditions: Arteriovenous Fistula

Summary: isometric exercise has been shown to increase the diameter and the blood flow rate of forearm veins.at present, more studies focus on the perioperative period to promote the maturation of arteriovenous fistula(avf), while there are few reports on functional maintenance measures for the patients with maintenance hemodialysis.this study aims to explore the effect of dumbbell exercise on avf，and evaluate whether patients can carry a 6-pound item with the fistula limb in a reasonable way.

autologous arteriovenous fistula (avf) is the preferred vascular access for maintenance hemodialysis patients. it is estimated that avf accounts for 85-90% of the permanent vascular access in chinese hemodialysis patients. with the prolongation of dialysis time, aging, and the increase of diabetes incidence, the complications of avf are more and more common, which affect the lifetime of avf. therefore,self-maintenance of avf is essential. among them, exercise should be used throughout the entire process of avf use for the reason that it is economical, easy to operate, and highly repeatable.the most common isometric exercise is handgrip exercise. however, there are some deficiencies in this exercise, such as lack of quantitative standards and burnout of repeated actions. as a result, this study uses quantitative dumbbells as a training tool to explore the effect of dumbbell exercise on the maintenance of avf, and further evaluates and breaks the nursing routine of "no lifting weights" of fistula limb.

Eligibility criteria:
inclusion criteria: 1. patients who have established arteriovenous fistula 2. patients whose muscle strength of the fistula limb is graded 4-5, which can overcome the 6-pound gravity and external resistance to complete the range of joint activity 3. patients who provided informed consent. exclusion criteria: 1. left ventricular cardiac ejection fraction \<30%; 2. using a arteriovenous graft or a long-term catheter as a permanent access; 3. the diameter of the aneurysm is greater than 2 cm or the aneurysm has a risk of rupture; 4. participation in other clinical trials at the same time; 5. severe cardiovascular diseases and other organ complications,malignant tumors, mental illnesses, etc.
safety study of sparc1104

Conditions: Spasticity

Summary: open-label, safety study of sparc1104 in subjects with spasticity due to multiple sclerosis

safety study of sparc1104

Eligibility criteria:
* willingness to participate and give written informed consent * men and women ≥ 18 years of age * sexually active women who are of child bearing potential will practice an acceptable method of birth control for the duration of the trial as judged by the investigator. examples of acceptable contraception are: condoms, foams, jellies, diaphragm, intrauterine device, oral or long-acting injected contraceptives, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or having a partner who is incapable of initiating conception. the practice of contraception must have started at least 3 months prior to trial entry. * if female, negative pregnancy test result at screening * diagnosed with ms and a known history of spasticity * meet one of the following criteria o subjects who completed the double-blind randomized withdrawal phase (part 3) of trial clr_09_21 with no major protocol violation

Keywords: spasticity
myocardial infarction register of the saarland

Conditions: Myocardial Infarction

Summary: the myocardial infarction register saarland (mir-sl), is intended to collect data about the treatment of patients suffering from st-elevation myocardial infarction (stemi). it aims to provide current data on the implementation of guidelines for both, the interventional and adjuvant drug therapy of stemi in daily clinical practice in the saarland.

the myocardial infarction register saarland (mir-sl), is intended to collect data about the treatment of patients suffering from st-elevation myocardial infarction (stemi). it aims to provide current data on the implementation of guidelines for both, the interventional and adjuvant drug therapy of stemi in daily clinical practice in the saarland. in order to obtain representative data for the saarland, preferably all consecutive patients should be documented comprehensively in the university hospital of the saarland, the non-university hospitals with cardiac catheterization laboratory as well as in hospitals without cardiac catheterization laboratory . mir-sl is attended by all 22 hospitals in saarland, that treat patients with acute stemi. a follow-up will be carried out after three months, 12 months and five years.

Eligibility criteria:
inclusion criteria: * signed informed consent exclusion criteria: * age \< 18 years * missing informed consent
open-label extension study of the long-term effects of migalastat hcl in patients with fabry disease

Conditions: Fabry Disease

Summary: this is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (hcl) for participants with fabry disease who completed treatment of a previous migalastat hcl study. the study assessed the long-term safety and effectiveness of migalastat hcl.


Eligibility criteria:
inclusion criteria: * participant had completed treatment in a previous study of migalastat hcl given as a monotherapy * male and female participant agreed to use protocol-identified acceptable contraception * participant was willing to provide written informed consent and authorization for use and disclosure of personal health information (phi) exclusion criteria: * participant's last available estimated glomerular filtration rate (egfr) in the previous study was \ 30 ml/min/1.73 m\^2 * participant had undergone, or was scheduled to undergo kidney transplantation or was currently on dialysis * participant had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before baseline visit * participant had clinically significant unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or new york heart association class iii or iv congestive heart failure) * participant had a history of allergy or sensitivity to at1001 (including excipients) or other iminosugars (for example, miglustat, miglitol) * participant required treatment with glyset® (miglitol) or zavesca® (miglustat) * participants with severe or unsuitable concomitant medical condition * participants with clinically significant abnormal laboratory value(s) and/or clinically significant electrocardiogram (ecg) findings

Keywords: amicus therapeutics galafold migalastat at1001
effects of workstation ergonomics and physiotherapy in cervicogenic headache.

Conditions: Cervicogenic Headache

Summary: cervicogenic headache (cgh) is a distinct form of headache and accounts for 17.8% of all headaches and the prevalence rate is between 0.4% and 20%. a guide to health and safety in the office handbook by common wealth of australia (2008) suggested the ergonomic guidance and interventions for preventing and treating musculoskeletal disorder (msd) injuries in the office workers. also, it has been estimated that 34% of us citizens receive some sort of physiotherapy for cgh each year. however, no studies have compared and investigated the combined and individual effects of workstation ergonomics, physiotherapy and patient education for improving cervicogenic headache and work ability in office workers.

cervicogenic headache (cgh) is a distinct form of headache and accounts for 17.8% of all headaches and the prevalence rate is between 0.4% and 20%. a guide to health and safety in the office handbook by common wealth of australia (2008) suggested the ergonomic guidance and interventions for preventing and treating musculoskeletal disorder (msd) injuries in the office workers. also, it has been estimated that 34% of us citizens receive some sort of physiotherapy for cgh each year. however, no studies have compared and investigated the combined and individual effects of workstation ergonomics, physiotherapy and patient education for improving cervicogenic headache and work ability in office workers. therefore, our study objective was intended to compare and investigate the combined and individual effects of workstation ergonomics, physiotherapy and patient education in improving cervicogenic headache and work ability in office workers. this randomized clinical trial hypothesized that there is a difference in primary and secondary outcome measures between workstation ergonomics, physiotherapy and patient education for improving cervicogenic headache and work ability in office workers.

Eligibility criteria:
inclusion criteria: patients aged between 18-60 years working in the computer ≥ 32 hrs/week suffering from cervicogenic headache (\>3 months) pain intensity ≥3 on a numerical pain rating scale (nprs), cervicogenic headache resulting from pain in the neck followed by headache, limited neck movements, neck muscle spasm, consent to participate in the study exclusion criteria: other primary headaches such as migraine and tension-type headaches (tth), whiplash injuries, participants who show signs of the five 'd's' (dizziness, drop attacks, dysarthria, dysphagia, diplopia) who have signs of the three 'n's (nystagmus, nausea, other neurological symptoms (cord compression or nerve root involvement), contraindications to physio therapy (congenital anomalies, tumor, degenerative and inflammatory arthritis, osteoporosis, dislocation, fractures, and steroid intake), underwent previous head and neck surgeries, had physiotherapy or other complementary therapies in the last three months

Keywords: workstation ergonomics physiotherapy randomized control trial office workers